Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 15.465 -0.42% -0.07
FOLD closed down 1.9 percent on Friday, July 10, 2020, on 29 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical FOLD trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish -0.42%
Wide Bands Range Expansion -0.42%
Overbought Stochastic Strength -0.42%
Wide Bands Range Expansion -2.31%
Overbought Stochastic Strength -2.31%
New 52 Week High Strength -2.00%
Wide Bands Range Expansion -2.00%
Overbought Stochastic Strength -2.00%
New 52 Week Closing High Bullish -2.67%
Outside Day Range Expansion -2.67%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Medicine Biopharmaceutical Rare Diseases Inborn Errors Of Metabolism Enzyme Replacement Therapy Lipid Storage Disorders Orphan Drugs Fabry Disease Gaucher Disease Lysosomal Storage Disorders Pompe Disease Protein Folding Rare And Orphan Diseases

Is FOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.13
52 Week Low 6.25
Average Volume 3,006,881
200-Day Moving Average 10.43
50-Day Moving Average 13.18
20-Day Moving Average 14.74
10-Day Moving Average 15.56
Average True Range 0.72
ADX 28.61
+DI 27.71
-DI 14.05
Chandelier Exit (Long, 3 ATRs ) 13.99
Chandelier Exit (Short, 3 ATRs ) 12.63
Upper Bollinger Band 17.67
Lower Bollinger Band 11.81
Percent B (%b) 0.64
BandWidth 39.75
MACD Line 0.84
MACD Signal Line 0.85
MACD Histogram -0.0168
Fundamentals Value
Market Cap 2.56 Billion
Num Shares 165 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.56
Price-to-Sales 135.92
Price-to-Book 7.22
PEG Ratio -0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.21
Resistance 3 (R3) 16.27 16.10 16.09
Resistance 2 (R2) 16.10 15.93 16.07 16.05
Resistance 1 (R1) 15.82 15.83 15.74 15.76 16.02
Pivot Point 15.65 15.65 15.61 15.62 15.65
Support 1 (S1) 15.37 15.48 15.29 15.31 15.04
Support 2 (S2) 15.20 15.38 15.17 15.01
Support 3 (S3) 14.92 15.20 14.97
Support 4 (S4) 14.86